Argenx & Fondation Maladies Rares Prix de recherche argenx « Recherche de nouvelles cibles d?anticorps pour les maladies rare neuromusculaires et/ou auto-immunes »
Fondation Maladies Rares Appel à projets OMICS : Omics approaches to study the genetic and molecular basis of rare diseases and improve their diagnosis
NIH NIA Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
NIH NINDS Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
NIH NINDS Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
NIH NIMH Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
